← Leaderboards
Craig E. Crosson
Medical University Of South Carolina
$7,932,196
Attributed
$7,932,196
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$10,984,154 · 6
By mechanism
R01$5,382,305 · 2
P20$3,051,958 · 1
P30$1,224,874 · 1
R24$1,045,017 · 1
U13$280,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Jerry G Webb$1,448,549
Others in their field
Top investigators on “Glaucoma”
- Rohit Varma · University Of Southern California$58,233,961
- Janey L Wiggs · Massachusetts Eye And Ear Infirmary$36,083,461
- Cecilia Sungmin Lee · University Of Washington$32,086,169
- David Huang · Cleveland Clinic Lerner Col/Med-Cwru$27,740,623
- Linda M Zangwill · University Of California San Diego$23,025,291
- Robert N Weinreb · University Of California, San Diego$21,784,031
Research focus
GlaucomaFundingResearch PersonnelProgramsLinkNerve DegenerationEventAdenosineAmericanPhosphoric Monoester HydrolasesMeetingsPhysiologic Intraocular PressureMediatingMatrix MetalloproteinasesResourcesIn VivoGrantOptic NerveCellsBaseDesignMetabolicPathway InteractionsRisk Factors
Grant awards (33)
ARVO Annual Meeting$70,000
U13 · FY2017 · EY · contact PI
LIPIDOMISC PORTAL AND SUSTANIABILITY PLAN$246,702
P30 · FY2016 · GM · contact PI
ARVO Annual Meeting$70,000
U13 · FY2016 · EY · contact PI
LIPIDOMISC PORTAL AND SUSTANIABILITY PLAN$246,702
P30 · FY2015 · GM · contact PI
ARVO Annual Meeting$70,000
U13 · FY2015 · EY · contact PI
Protein Acetylation in Glaucomatous Optic Neuropathy$361,375
R01 · FY2014 · EY · contact PI
LIPIDOMISC PORTAL AND SUSTANIABILITY PLAN$246,702
P30 · FY2014 · GM · contact PI
ARVO Annual Meeting$70,000
U13 · FY2014 · EY · contact PI
Protein Acetylation in Glaucomatous Optic Neuropathy$350,313
R01 · FY2013 · EY · contact PI
LIPIDOMISC PORTAL AND SUSTANIABILITY PLAN$238,068
P30 · FY2013 · GM · contact PI
Protein Acetylation in Glaucomatous Optic Neuropathy$368,750
R01 · FY2012 · EY · contact PI
LIPIDOMISC PORTAL AND SUSTANIABILITY PLAN$246,700
P30 · FY2012 · GM · contact PI
COBRE in Lipidomics and Pathobiology$2,124,738
P20 · FY2011 · RR · contact PI
Protein Acetylation in Glaucomatous Optic Neuropathy$368,750
R01 · FY2011 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$373,045
R01 · FY2010 · EY · contact PI
COBRE in Lipidomics and Pathobiology$927,220
P20 · FY2009 · RR · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$365,967
R01 · FY2009 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$281,462
R01 · FY2009 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$348,315
R01 · FY2008 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$345,194
R01 · FY2007 · EY · contact PI
Core Resources for Vision Research at MUSC$198,478
R24 · FY2007 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$428,160
R01 · FY2006 · EY · contact PI
Core Resources for Vision Research at MUSC$192,694
R24 · FY2006 · EY · contact PI
Adenosine Agonists: Potential Antiglaucoma Agents$286,000
R01 · FY2005 · EY
Core Resources for Vision Research at MUSC$187,084
R24 · FY2005 · EY
Adenosine Agonists: Potential Antiglaucoma Agents$333,370
R01 · FY2004 · EY
Core Resources for Vision Research at MUSC$181,636
R24 · FY2004 · EY
Adenosine Agonists: Potential Antiglaucoma Agents$11,242
R01 · FY2004 · EY
Adenosine Agonists: Potential Antiglaucoma Agents$331,990
R01 · FY2003 · EY
Core Resources for Vision Research at MUSC$285,125
R24 · FY2003 · EY
Adenosine Agonists: Potential Antiglaucoma Agents$286,000
R01 · FY2002 · EY
Adenosine Agonists: Potential Antiglaucoma Agents$286,000
R01 · FY2001 · EY
ADENOSINE AGONISTS--POTENTIAL ANTIGLAUCOMA DRUGS$256,372
R01 · FY2000 · EY